Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Hepatocellular Cancer

In brief

The purpose of this study is to learn about the effect of the investigational agent tivozanib on the control of the tumor growth in hepatocellular (liver) cancer. The investigators also plan to collect information on the likelihood to develop side effects while on this treatment. Tivozanib is an oral medication (pill) taken once a day. This medication is designed to stop the tumor from developing new blood vessels.

Key facts

Study ID

NCT01807156

Run by

Emory University

People needed

7

Starts

2013-03-01

Expected to finish

2015-02-01

Last updated by the study team

2016-04-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with measurable, histological diagnosis of hepatocellular carcinoma (HCC) and whose disease is not amenable to surgical or regional therapy.
• Prior allowed therapy:
• Surgery including hepatic resection
• Minimum of 4 weeks since any surgical procedure.
• Patients must have adequately recovered from surgery.
• Regional therapy
• Includes transarterial chemoembolization (TACE), drug-eluting bead [DEB]-TACE, percutaneous ethanol injection, radiofrequency/cryo ablation, Yttrium-90 radioembolization.
• More than 2 weeks must have lapsed from therapy.
• There must be an indicator lesion outside the treated area or clear evidence of progression in the treated lesion, not amenable for further local therapies.
• Concomitant sorafenib with regional therapy is allowed as long as no evidence of progression on sorafenib.
• Prior adjuvant sorafenib is allowed, if completed more than 6 months prior to disease recurrence.
• Adequate hematological, liver and metabolic organ function.
• Signed informed consent.

You may not qualify if…

• Patients with mixed histology or fibrolamellar variant.
• Prior systemic therapy for metastatic disease.
• Uncontrolled hypertension (HTN).
• Symptomatic heart failure.

Where it is running

• Emory University, Winship Cancer Institute — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.